JP2017533223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533223A5 JP2017533223A5 JP2017523507A JP2017523507A JP2017533223A5 JP 2017533223 A5 JP2017533223 A5 JP 2017533223A5 JP 2017523507 A JP2017523507 A JP 2017523507A JP 2017523507 A JP2017523507 A JP 2017523507A JP 2017533223 A5 JP2017533223 A5 JP 2017533223A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- composition
- administered
- platin
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123237 Taxane Drugs 0.000 claims description 20
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 18
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 18
- 229940125904 compound 1 Drugs 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 6
- 229960004562 carboplatin Drugs 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- FIYXUOWXHWJDAM-UHFFFAOYSA-N methyl sulfamate Chemical compound COS(N)(=O)=O FIYXUOWXHWJDAM-UHFFFAOYSA-N 0.000 claims description 3
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229950007221 nedaplatin Drugs 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229950005566 picoplatin Drugs 0.000 claims description 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 2
- 229960005399 satraplatin Drugs 0.000 claims description 2
- 190014017285 satraplatin Chemical compound 0.000 claims description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- KJDAGXLMHXUAGV-DGWLBADLSA-N [(1r,2r,3s,4r)-2,3-dihydroxy-4-[[2-[3-(trifluoromethylsulfanyl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]cyclopentyl]methyl sulfamate Chemical compound O[C@@H]1[C@H](O)[C@@H](COS(=O)(=O)N)C[C@H]1NC1=CC=NC2=CC(C=3C=C(SC(F)(F)F)C=CC=3)=NN12 KJDAGXLMHXUAGV-DGWLBADLSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 3- (trifluoromethylthio) phenyl Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072311P | 2014-10-29 | 2014-10-29 | |
| US62/072,311 | 2014-10-29 | ||
| PCT/US2015/057062 WO2016069392A1 (en) | 2014-10-29 | 2015-10-23 | Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533223A JP2017533223A (ja) | 2017-11-09 |
| JP2017533223A5 true JP2017533223A5 (enExample) | 2018-11-29 |
| JP6698648B2 JP6698648B2 (ja) | 2020-05-27 |
Family
ID=55858197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523507A Active JP6698648B2 (ja) | 2014-10-29 | 2015-10-23 | ユビキチン活性化酵素阻害物質及び化学療法剤の投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180133221A1 (enExample) |
| EP (1) | EP3212650B1 (enExample) |
| JP (1) | JP6698648B2 (enExample) |
| TW (1) | TW201625256A (enExample) |
| WO (1) | WO2016069392A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ras相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1989206E (pt) * | 2006-02-02 | 2012-10-15 | Millennium Pharm Inc | Inibidores da enzima de ativação e1 |
| US8008307B2 (en) * | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| WO2013123169A1 (en) | 2012-02-17 | 2013-08-22 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
-
2015
- 2015-10-23 WO PCT/US2015/057062 patent/WO2016069392A1/en not_active Ceased
- 2015-10-23 JP JP2017523507A patent/JP6698648B2/ja active Active
- 2015-10-23 EP EP15853752.2A patent/EP3212650B1/en active Active
- 2015-10-23 US US15/522,715 patent/US20180133221A1/en not_active Abandoned
- 2015-10-23 TW TW104135008A patent/TW201625256A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533223A5 (enExample) | ||
| Postiglione et al. | Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies | |
| Ruggiero et al. | Platinum compounds in children with cancer: toxicity and clinical management | |
| Helm et al. | Enhancing the efficacy of cisplatin in ovarian cancer treatment–could arsenic have a role | |
| JP2009514880A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| JP2009514881A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2014512356A5 (enExample) | ||
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| JP2006504723A5 (enExample) | ||
| JP2012520323A5 (enExample) | ||
| JP2012082234A5 (enExample) | ||
| JP2005511597A5 (enExample) | ||
| HRP20110245T1 (hr) | Derivati pirazolopirimidina kao inhibitori o ciklinu ovisne kinaze | |
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| RU2013148732A (ru) | Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения | |
| RU2013102398A (ru) | Лечение рака крови | |
| JP2016520528A5 (enExample) | ||
| NZ630392A (en) | Methods of treating lung cancer | |
| JP2017514800A5 (enExample) | ||
| JP2017533221A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| JP2017527582A5 (enExample) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения |